Abstract:A healthy host-microbiome relationship, crucial for intestinal homeostasis, is established early in postnatal life. Imbalance in the neonatal microbiome may lead to the development of chronic pathological conditions later in life. Dysbiosis of the gut microbiota is increasingly being linked to the etiology of both intestinal and systemic illnesses such as irritable bowel disease (IBD), cardiovascular diseases and diabetes, as well as kidney and neurological disorders. Gut dysbiosis also leads to the development of colorectal cancer (CRC). Despite substantial research, little is known about the interactions between microorganisms, their hosts, and their environments, or whether dysbiosis is a cause or consequence of disease. According to a recent hypothesis, bacterial species living in the mucus layer of the colon may determine whether cellular homeostasis is retained or inflammatory processes are elicited, either through direct interaction with intestinal epithelium or indirectly via bacterial metabolites. Recently, high throughput deep-sequencing technology has enabled the characterization of the microbiota in patients suffering from intestinal or extra-intestinal disorders, and a strong association between dysbiosis and disease development was found. However, specific disease drivers still need to be identified in most cases. Small compounds and metabolites produced by gut bacterial flora act as signaling molecules, such as neurotransmitters and neuropeptides that can profoundly influence host physiology. These metabolites play a crucial role in modulating gut-brain crosstalk. There is growing evidence that neurological disorders such as Alzheimer's disease, Parkinson’s and others, may originate or be exaggerated in response to microbial dysbiosis either directly or indirectly interfering with the drugs through metabolites. The present evidence on the role of the gut microbiota in disease development and drug metabolism is summarized in this review. Based on available studies, we can explore the potential of gut flora to alleviate disease progression.

Gut Microbiome - Should we treat the gut and not the bones?

Roles of Gut Microbiome in Bone Homeostasis and Its Relationship with Bone-Related Diseases

Relationship between Gut Microbiota and Bone Health

The role of gut microbiota in bone homeostasis

Gut Microbiota, Immune System, and Bone

Modulation of bone remodeling by the gut microbiota: a new therapy for osteoporosis

Microbiome's role in musculoskeletal health through the gut-bone axis insights

Unequivocal Dyad of Gut Microbiome and Osteo Integrity- Dynamic Cross-Talk and Implications in Osteoporosis Management

"Osteomicrobiology": The Nexus Between Bone and Bugs

Musculoskeletal microbiology: The utility of the microbiome in orthopedics

Gut Microbiota and Bone Diseases: A Growing Partnership

Progress of linking gut microbiota and musculoskeletal health: casualty, mechanisms, and translational values

Mechanism of action of gut microbiota and probiotic Lactobacillus rhamnosus GG on skeletal remodeling in mice

The microbiota-gut-bone axis and bone health

From gut to bone: deciphering the impact of gut microbiota on osteoporosis pathogenesis and management

Dysbiosis: Gut feeling

The Gut Microbiome: a Potential Therapeutic Path in Complementary Medicine

Gut microbiota-bile acid-skeletal muscle axis

The Link Between the Gut Microbiome and Bone Metastasis

Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases

Gut commensals and their metabolites in health and disease